Modulation of Inflammation by Mesenchymal Stem Cell Transplantation in Peritoneal Dialysis in Rats

Abstract

Aim: The purpose of this study was to determine the effect of mesenchymal stem cell (MSC) transplantation on the peritoneal morphology and inflammation markers in rat models of peritoneal dialysis (PD). Materials and methods: Wistar albino rats were divided into two groups: control (C) (n ¼ 8) and experimental groups (n ¼ 50). PD solution was given to the experimental group during 6 weeks. Then, experimental group was divided into three groups as PD, MSC, and placebo (P) groups. MSC group was treated with MSC (1.5 Â 10 6 cells/kg) and P group was treated with phosphate buffer solution via intraperitoneal injection. Evaluation was performed to C and PD groups at the end of 6 weeks and to MSC and P groups at second and third week of the treatment (MSC-2, P-2, MSC-3, and P-3 groups). Results: The submesothelial area was significantly thickened in PD and P groups compared to C and MSC groups. Peritoneal fibrosis was seen in P-3 group but not in MSC group. There were no significant differences between the MSC-3 and C groups according to morphological findings. Levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly increased in MSC-2 group compared to the other groups (p-values ranged from 0.0001 to 0.04). TNF-α and IL-6 levels in MSC-3 and P-3 groups were lower than PD and C groups (p < 0.0001 for TNF-α and p ¼ 0.0001-0.002 for IL-6). Conclusion: Giving MSC may protect the peritoneal membrane from the deleterious effect of PD and extend the life of the peritoneal membrane. Our study is the first on this issue and more detailed studies are needed.

The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis

“…Unfortunately, however, improvements attainable by such a treatment appeared to be only minor [20]. However, rat BM‐MSC transplantation intraperitoneally in peritoneal fibrosis induced by dialysis may protect the peritoneal membrane from the deleterious effect of PD [64]. Similarly, HUMSC transplantation significantly ameliorated the PD/MGO 3W‐induced peritoneal fibrosis to nearly normal levels following 3 weeks of intraperitoneal transplantation in this study.…”

Protection of the Peritoneal Membrane by Peritoneal Dialysis Effluent-Derived Mesenchymal Stromal Cells in a Rat Model of Chronic Peritoneal Dialysis

“…However, whether all of these pathways or just some of them are required for the MSC functions in the reduction or repair of the peritoneum injury remains to be further investigated. IP injected MSCs can be localized in the mesothelium line [37], but only until day 3 [39], and by then, these MSCs are colocalized but not merged with injured mesothelial cells [38]. In the present study, we did not specifically track the migration and/or possible differentiation of pMSCs after IP injection in rats.…”

“…Recently, there has been an increasing interest in using MSCs to protect the PM of PD patients from injury during PD. IP injection of rat BM-MSCs or AD-MSCs significantly reduces PD solution-induced submesothelial thickness and cellular infiltration of the PM [37, 38] as well as chlorhexidine gluconate-induced peritoneal fibrosis in rats [39, 40]. Similar to the results from this study, treatment with human umbilical cord-derived MSCs prevents methylglyoxal/PD solution-induced peritoneal alterations including peritoneal thickening, fibrosis, and neoangiogenesis, which is associated with the protection of UF (both fluid removal and glucose and creatinine clearance) [41].…”

Adipose derived stem cells isolated from omentum: A novel source of chemokines for ovarian cancer growth

“…[2] MSCs derived soluble factors such as indolamine 2,3-dioxygenase, [3] prostaglandin E2 and transforming growth factor-β1 (TGFβ1), [4] along with direct cell to cell contact [5] are main mechanisms of immune-modulatory functions of MSCs. Moreover, MSCs mediate their tumor promoting effects through producing a variety of cytokines and growth factors [6] such as interleukin-6 (IL-6), [7] CCL5 (RANTES) [8] and CXCL-12 (stromal cell-derived factor-1 [SDF-1]). [9] High expression of CXCR4 was shown in poorly differentiated region of papillary thyroid carcinoma.…”